An Ignoble Experiment

Karl Lennert

S A Pileri

Leukemia 2013 27: 517-518; 10.1038/leu.2012.335

Lymphoma ‘type K.’—in memory of Karl Lennert (1921–2012)

W Klapper, K Koch, U Mechler, C Borck, E Fuhry and R Siebert

Leukemia 2013 27: 519-521; 10.1038/leu.2012.334

A collection of memories of Professor Karl Lennert

P Banks, E Campo, E S Jaffe, M C Kinney, R D Collins, M A Piris and S H Swerdlow

Leukemia 2013 27: 522; 10.1038/leu.2012.340

Spotlight Review

SPOTLIGHT ON SIGNALING PATHWAYS REGULATING HUMAN STEM CELLS

Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms

V Radulović, G de Haan and K Klauke

Leukemia 2013 27: 523-533; advance online publication, December 21, 2012; 10.1038/leu.2012.368

Reviews

Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions

M T S Bertilaccio, C Scielzo, G Simonetti, E Ten Hacken, B Apollonio, P Ghia and F Caligaris-Cappio

Leukemia 2012 27: 534-540; advance online publication, September 13, 2012; 10.1038/leu.2012.268

B-lineage transcription factors and cooperating gene lesions required for leukemia development

E Tijchon, J Havinga, F N van Leeuwen and B Scheijen

Leukemia 2013 27: 541-552; advance online publication, October 10, 2012; 10.1038/leu.2012.293

The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia

E Truelove, A K Fielding and B J Hunt

Leukemia 2013 27: 553-559; advance online publication, October 9, 2012; 10.1038/leu.2012.290

Original Articles

MOLECULAR TARGETS FOR THERAPY

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target Open

S A Hartsink-Segers, C M Zwaan, C Exalto, M W J Luijendijk, V S Calvert, E F Petricoin, W E Evans, D Reinhardt, V de Haas, M Hedtjärn, B R Hansen, T Koch, H N Caron, R Pieters and M L Den Boer

Leukemia 2013 27: 560-568; advance online publication, September 3, 2012; 10.1038/leu.2012.256

ACUTE LEUKEMIAS

Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia

K Morrow, C P Hernandez, P Raber, L Del Valle, A M Wilk, S Majumdar, D Wyczechowska, K Reiss and P C Rodriguez

Leukemia 2013 27: 569-577; advance online publication, August 28, 2012; 10.1038/leu.2012.247

GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia

T Holmlund, M J Lindberg, D Grander and A E Wallberg

Leukemia 2013 27: 578-585; advance online publication, September 11, 2012; 10.1038/leu.2012.265

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

M R Janes, C Vu, S Mallya, M P Shieh, J J Limon, L-S Li, K A Jessen, M B Martin, P Ren, M B Lilly, L S Sender, Y Liu, C Rommel and D A Fruman

Leukemia 2013 27: 586-594; advance online publication, October 1, 2012; 10.1038/leu.2012.276

Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene

M Díaz-Beyá, A Navarro, G Ferrer, T Díaz, B Gel, M Camós, M Pratcorona, M Torrebadell, M Rozman, D Colomer, M Monzo and J Esteve

Leukemia 2013 27: 595-603; advance online publication, October 1, 2012; 10.1038/leu.2012.278

MYELODYSPLASIAS

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings

N Kröger, T Zabelina, L de Wreede, J Berger, H Alchalby, A van Biezen, N Milpied, L Volin, M Mohty, V Leblond, D Blaise, J Finke, N Schaap, M Robin and T de Witte on behalf of the MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Leukemia 2013 27: 604-609; advance online publication, July 23, 2012; 10.1038/leu.2012.210

Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes

M del Rey, K O'Hagan, M Dellett, S Aibar, H A A Colyer, M E Alonso, M Díez-Campelo, R N Armstrong, D J Sharpe, N C Gutiérrez, J L García, J De Las Rivas, K I Mills and J M Hernández-Rivas

Leukemia 2013 27: 610-618; advance online publication, August 31, 2012; 10.1038/leu.2012.253

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

C/EBPβ promotes BCR–ABL-mediated myeloid expansion and leukemic stem cell exhaustion

Y Hayashi, H Hirai, N Kamio, H Yao, S Yoshioka, Y Miura, E Ashihara, Y Fujiyama, D G Tenen and T Maekawa

Leukemia 2013 27: 619-628; advance online publication, September 5, 2012; 10.1038/leu.2012.258

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability

A Slupianek, R Falinski, P Znojek, T Stoklosa, S Flis, V Doneddu, D Pytel, E Synowiec, J Blasiak, A Bellacosa and T Skorski

Leukemia 2013 27: 629-634; advance online publication, October 9, 2012; 10.1038/leu.2012.294

MINIMAL RESIDUAL DISEASE

Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia

B Denys, A J van der Sluijs-Gelling, C Homburg, C E van der Schoot, V de Haas, J Philippé, R Pieters, J J M van Dongen and V H J van der Velden

Leukemia 2013 27: 635-641; advance online publication, August 16, 2012; 10.1038/leu.2012.231

IMMUNOLOGY

Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1 Open

R Oostvogels, M C Minnema, M van Elk, R M Spaapen, G D te Raa, B Giovannone, A Buijs, D van Baarle, A P Kater, M Griffioen, E Spierings, H M Lokhorst and T Mutis

Leukemia 2013 27: 642-649; advance online publication, October 1, 2012; 10.1038/leu.2012.277

ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

C Shepherd, L Banerjee, C W Cheung, M R Mansour, S Jenkinson, R E Gale and A Khwaja

Leukemia 2013 27: 650-660; advance online publication, October 5, 2012; 10.1038/leu.2012.285

ANIMAL MODELS

MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia Open

M Clarke, S Dumon, C Ward, R Jäger, S Freeman, B Dawood, L Sheriff, M Lorvellec, R Kralovics, J Frampton and P García

Leukemia 2013 27: 661-670; advance online publication, August 22, 2012; 10.1038/leu.2012.241

LYMPHOMA

Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma

V Bohle, C Döring, M-L Hansmann and R Küppers

Leukemia 2013 27: 671-679; advance online publication, October 1, 2012; 10.1038/leu.2012.280

MYELOMA

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

G Bianchi, R A Kyle, D R Larson, T E Witzig, S Kumar, A Dispenzieri, W G Morice and S V Rajkumar

Leukemia 2013 27: 680-685; advance online publication, August 20, 2012; 10.1038/leu.2012.237

MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC

D-J Min, T Ezponda, M K Kim, C M Will, E Martinez-Garcia, R Popovic, V Basrur, K S Elenitoba-Johnson and J D Licht

Leukemia 2013 27: 686-694; advance online publication, September 13, 2012; 10.1038/leu.2012.269

Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients

P Falco, F Cavallo, A Larocca, D Rossi, T Guglielmelli, A Rocci, M Grasso, M L M Siez, L De Paoli, S Oliva, S Molica, R Mina, F Gay, G Benevolo, P Musto, P Omedè, R Freilone, S Bringhen, A M Carella, G Gaidano, M Boccadoro and A Palumbo

Leukemia 2013 27: 695-701; advance online publication, September 21, 2012; 10.1038/leu.2012.271

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

Y Zheng, J Yang, J Qian, P Qiu, S Hanabuchi, Y Lu, Z Wang, Z Liu, H Li, J He, P Lin, D Weber, R E Davis, L Kwak, Z Cai and Q Yi

Leukemia 2013 27: 702-710; advance online publication, September 21, 2012; 10.1038/leu.2012.272

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

H Avet-Loiseau, B G M Durie, M Cavo, M Attal, N Gutierrez, J Haessler, H Goldschmidt, R Hajek, J H Lee, O Sezer, B Barlogie, J Crowley, R Fonseca, N Testoni, F Ross, S V Rajkumar, P Sonneveld, J Lahuerta, P Moreau and G Morgan on behalf of the International Myeloma Working Group

Leukemia 2013 27: 711-717; advance online publication, October 3, 2012; 10.1038/leu.2012.282

Letters to the Editor

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression

S Bomken, L Buechler, K Rehe, F Ponthan, A Elder, H Blair, C M Bacon, J Vormoor and O Heidenreich

Leukemia 2013 27: 718-721; advance online publication, July 18, 2012; 10.1038/leu.2012.206

Lipoprotein lipase expression in unmutated CLL patients is the consequence of a demethylation process induced by the microenvironment

P Moreno, C Abreu, M Borge, F Palacios, P Morande, M Pegazzano, S Bianchi, A I Landoni, R Agrelo, M Giordano, G Dighiero, R Gamberale and P Oppezzo

Leukemia 2013 27: 721-725; advance online publication, July 25, 2012; 10.1038/leu.2012.212

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

G Ramsingh, P Westervelt, A F Cashen, G L Uy, K Stockerl-Goldstein, C N Abboud, N Bernabe, R Monahan, J F DiPersio and R Vij

Leukemia 2013 27: 725-728; advance online publication, July 25, 2012; 10.1038/leu.2012.214

The proportion of CD34⁺CD38^{low or neg} myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia

M Roshal, S Chien, M Othus, B L Wood, M Fang, F R Appelbaum, E H Estey, T Papayannopoulou and P S Becker

Leukemia 2013 27: 728-731; advance online publication, July 31, 2012; 10.1038/leu.2012.217

Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421

M M O'Brien, X Cao, S Pounds, G V Dahl, S C Raimondi, N J Lacayo, J Taub, M Chang, H J Weinstein, Y Ravindranath, H Inaba, D Campana, C H Pui and J E Rubnitz

Leukemia 2013 27: 731-734; advance online publication, August 3, 2012; 10.1038/leu.2012.223

The clinical relevance of BAALC and ERG expression levels in pediatric AML

M C H Hermkens, M M van den Heuvel-Eibrink, S T C J M Arentsen-Peters, A Baruchel, J Stary, D Reinhardt, M Zimmerman, V de Haas, R Pieters and C M Zwaan

Leukemia 2013 27: 735-737; advance online publication, August 16, 2012; 10.1038/leu.2012.233

A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient

R Hoogeboom, T A Wormhoudt, M R Schipperus, A W Langerak, D K Dunn-Walters, J E J Guikema, R J Bende and C J M van Noesel

Leukemia 2013 27: 738-740; advance online publication, August 20, 2012; 10.1038/leu.2012.238

Trisomy 12 CLLs progress through NOTCH1 mutations

V Balatti, S Lerner, L Rizzotto, L Z Rassenti, A Bottoni, A Palamarchuk, L Cascione, H Alder, M J Keating, T J Kipps, Y Pekarsky and C M Croce

Leukemia 2013 27: 740-743; advance online publication, August 20, 2012; 10.1038/leu.2012.239

Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells

C Preisinger, J P Schwarz, O B Bleijerveld, E Corradini, P J Müller, K I Anderson, W Kolch, A Scholten and A J R Heck

Leukemia 2013 27: 743-746; advance online publication, August 27, 2012; 10.1038/leu.2012.243

Are ARID5B and IKZF1 polymorphisms also associated with childhood acute myeloblastic leukemia: the ESCALE study (SFCE)?

J Rudant, L Orsi, A Bonaventure, S Goujon-Bellec, E Corda, A Baruchel, Y Bertrand, B Nelken, A Robert, G Michel, N Sirvent, P Chastagner, S Ducassou, X Rialland, D Hémon, G Leverger and J Clavel

Leukemia 2013 27: 746-748; advance online publication, August 27, 2012; 10.1038/leu.2012.244

Identification of a Wilms’ tumor 1-derived immunogenic CD4⁺ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes

S Anguille, F Fujiki, E L Smits, Y Oji, E Lion, Y Oka, Z N Berneman and H Sugiyama

Leukemia 2013 27: 748-750; advance online publication, August 29, 2012; 10.1038/leu.2012.248

Analysis of NUP98/NSD1 translocations in adult AML and MDS patients

F Thol, B Kölking, I H I Hollink, F Damm, M M van den Heuvel-Eibrink, C Michel Zwaan, G Bug, O Ottmann, K Wagner, M Morgan, W K Hofmann, G Göhring, B Schlegelberger, J Krauter, A Ganser and M Heuser

Leukemia 2013 27: 750-754; advance online publication, August 29, 2012; 10.1038/leu.2012.249

Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals

J Du, Y Liu, B Meline, G Kong, L X Tan, J C Lo, J Wang, E Ranheim, L Zhang, Y I Chang, M J Ryu, J F Zhang and J Zhang

Leukemia 2013 27: 754-757; advance online publication, August 31, 2012; 10.1038/leu.2012.251

Corrigendum

Impact of bivalirudin and genous stent in patients with acute myeloid leukemia undergoing emergency percutaneous coronary angioplasty for acute coronary syndrome

G Galasso, T Niglio, S De Luca, C De Biase, V Parisi and F Piscione

Leukemia 2013 27: 758; 10.1038/leu.2012.320